Clinical Trial Update: The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU [Phase 2]

View source ↗

Summary

Phase 2 trial assessing tolerance of the antiviral FIAU (fialuridine) in HIV-infected patients with herpes group virus infections; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Herpes Simplex Infection
• Human Immunodeficiency Virus Infection

Drugs mentioned

• FIAU (fialuridine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Herpes Simplex, HIV Infections | Phase 2 | Status: COMPLETED